Palatin Technologies Inc
palatin.comWhat Do They Do?
Develops melanocortin receptor medicines, including obesity treatments and therapies for inflammatory and autoimmune diseases, for pharmaceutical partners and potential licensees.
10-K for FY2026, filed Sep 28, 2026Palatin™ is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the…View ↗
Our product development activities focus primarily on use of MC4R agonists for treatment of obesity. The Company is developing MC4R…View ↗
Activities in inflammation disease indications focus primarily on development of MCR peptides for ocular conditions, and in the gut and…View ↗
Partnered and Out-Licensing Development Programs. In addition to our internally focused MC4R obesity development programs, our strategy…View ↗
How Do They Make Money?
Pharmaceutical partners pay for licenses through upfront payments, development and sales milestones, and royalties if products are sold; partners also reimburse research services as the work is performed.
10-K for FY2026, filed Sep 28, 2026Retinal Disease Collaboration with Boehringer Ingelheim. In August 2025, we entered into a research collaboration, license and patent…View ↗
PL9643 for Dry Eye Disease. PL9643 is a peptide melanocortin agonist active at multiple melanocortin receptors, including MC1R and MC5R…View ↗
Revenue Recognition. For licenses of intellectual property, we assess at contract inception whether the intellectual property is distinct…View ↗
Research, development and regulatory milestone payments are considered variable consideration subject to constraint and excluded from the…View ↗
Sales-based royalty and milestone payments resulting from customer contracts solely or predominately for the license of intellectual…View ↗
We recognize revenue for research and development services under customer agreements as the services are performed. We record these…View ↗
$8.8M
-
10-K for FY2026, filed Sep 28, 2026
$8.8M ↗
Who Are Their Customers?
Pharmaceutical and biotechnology companies partner with Palatin to develop and commercialize medicines; the company also licenses product rights to partners.
10-K for FY2026, filed Sep 28, 2026Palatin™ is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the…View ↗
Activities in inflammation disease indications focus primarily on development of MCR peptides for ocular conditions, and in the gut and…View ↗
Entering into strategic collaborations, licensing arrangements and other partnerships with pharmaceutical and biotechnology companies and…View ↗
Partnered and Out-Licensing Development Programs. In addition to our internally focused MC4R obesity development programs, our strategy…View ↗
Retinal Disease Collaboration with Boehringer Ingelheim. In August 2025, we entered into a research collaboration, license and patent…View ↗
PL9643 for Dry Eye Disease. PL9643 is a peptide melanocortin agonist active at multiple melanocortin receptors, including MC1R and MC5R…View ↗
Do Revenues Turn Into Profits?
No. It lost $8.4M in FY2026.
10-K for FY2026, filed Sep 28, 2026
−$8.7MView ↗
10-K for FY2026, filed Sep 28, 2026
−$8.4MView ↗
10-K for FY2026, filed Sep 28, 2026
−$13.6MView ↗
How Are They Changing?
Growing. Revenue grew 6.0x in 4 years, from $1.5M in FY2022 to $8.8M in FY2026, about 57% a year.
Focus on obesity medicines
The older report centered on inflammatory and autoimmune diseases, including eye, gut and kidney conditions, alongside Vyleesi. The latest report centers product development on obesity medicines for rare neuroendocrine and related disorders, while inflammation programs are secondary or partnered.
10-K for FY2023, filed Sep 28, 2023 10-K for FY2026, filed Sep 28, 2026Our new product development activities in inflammation disease indications focus primarily on development of MCr peptides for ocular…View ↗
Our U.S. Food and Drug Administration (“FDA”) approved melanocortin receptor agonist, Vyleesi® (bremelanotide injection), is an “as needed”…View ↗
Our Current Product Development Strategy. We are designing and developing potent and highly selective MC1r agonist peptides and agonist…View ↗
Our product development activities focus primarily on use of MC4R agonists for treatment of obesity. The Company is developing MC4R…View ↗
Our Current Product Development Strategy. Our product development activities focus primarily on use of MC4R agonists for treatment of…View ↗
The Company is also developing, subject to the availability of resources, melanocortin receptor agonists with potential utility in ocular…View ↗
Vyleesi rights sold
The older report described Palatin marketing Vyleesi in the United States and pursuing additional licensing. The latest report says the Vyleesi assets were sold to Cosette, and presents the company as focused on developing and partnering its other medicines.
10-K for FY2023, filed Sep 28, 2023 10-K for FY2026, filed Sep 28, 2026Maximizing revenue from Vyleesi by marketing Vyleesi in the United States, supporting our existing licensees for China and Korea, and…View ↗
Vyleesi for HSDD. Vyleesi, the registered trademark for bremelanotide injection, was approved by the FDA on June 21, 2019 for the treatment…View ↗
Vyleesi is distributed nationally through a home delivery specialty pharmacy. Our marketing strategy focuses on efforts to establish…View ↗
Who Do They Compete With?
Competes with Rhythm Pharmaceuticals, Addyi, Sprout Pharmaceuticals, VYKAT XR, Allergan, and Novartis
10-K for FY2026, filed Sep 28, 2026Our most direct competitor in rare MC4R pathway diseases is Rhythm Pharmaceuticals, Inc. Rhythm markets IMCIVREE® (setmelanotide), an MC4R…View ↗
Loading...
